CN104547610A - Medicine composition for treating community acquired pneumonia - Google Patents
Medicine composition for treating community acquired pneumonia Download PDFInfo
- Publication number
- CN104547610A CN104547610A CN201410821867.3A CN201410821867A CN104547610A CN 104547610 A CN104547610 A CN 104547610A CN 201410821867 A CN201410821867 A CN 201410821867A CN 104547610 A CN104547610 A CN 104547610A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- pharmaceutical composition
- acquired pneumonia
- community acquired
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
- A61K36/428—Trichosanthes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/748—Oldenlandia or Hedyotis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8967—Lilium, e.g. tiger lily or Easter lily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8968—Ophiopogon (Lilyturf)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of medicine and particularly relates to a medicine composition for treating community acquired pneumonia. The medicine composition comprises the following ingredients: radix pseudostellariae, astragalus mongholicus, radix ophiopogonis, polygonatum odoratum, ginseng rootlets, lily, radices trichosanthis, dendrobe, herba hedyotis and liquorice. The medicine composition comprises pure Chinese herbal medicines, has effects of tonifying qi, strengthening body resistance, nourishing blood and promoting production of body fluid, has medicine-syndrome correspondence to the community acquired pneumonia, particularly the community acquired pneumonia caused by deficiency of both qi and yin, and has an obvious curative effect.
Description
Technical field
The invention belongs to medical art, be specifically related to a kind of pharmaceutical composition for the treatment of community acquired pneumonia.
Background technology
Community acquired pneumonia belongs to the disease such as " pathogenic wind-warm ", " winter-warm syndrome ", " pyretic pulmonary disease " in fever caused by exogenous pathogenic factors in the traditional Chinese medical science.Wind-warm lung-heat disease violates lung by wind heat pathogenic factor, and heat stops up lung qi, and caused by impairment of purifying function of the lung, to generate heat, cough, chest pain etc. are main clinical manifestation.Being equivalent to Acute Lung inflammatory lesion, belonging to tcm internal medicine exogenous disease research field, is commonly encountered diseases and the frequently-occurring disease of tcm internal medicine.
Current western medicine mainly adopts second and third cephalosporin in generation, beta-lactam class, fluoroquinolones is treated, though there is certain curative effect, along with the transition of pathogenic microorganism, drug resistance phenomenon is on the rise, and side effect is comparatively large, some drugs is expensive, therefore is difficult to popularity, Chinese medicine then demonstrates huge advantage improving symptom and sign, Shorten the Treatment Process and improve in overall treatment effect, and the Chinese medicine composition for this reason studying effective treatment community acquired pneumonia is very necessary.
Summary of the invention
The invention provides a kind of new pharmaceutical composition for the treatment of community acquired pneumonia, this pharmaceutical composition is rapid-action, good effect, toxic and side effects is little, and it is obtained by following raw material: Radix Pseudostellariae, the Radix Astragali, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Leptoradix Ginseng, Bulbus Lilii, Radix Trichosanthis, Herba Dendrobii, Herba Hedyotidis Diffusae, Radix Glycyrrhizae.
In pharmaceutical composition of the present invention, described Radix Pseudostellariae, sweet, micro-hardship, flat.Return spleen, lung meridian.Replenishing QI to invigorate the spleen, promoting the production of body fluid for nourishing the lung.Tired for insufficiency of the spleen body, inappetence, weak after being ill, deficiency of both vital energy and Yin, spontaneous perspiration is thirsty, dryness of the lung dry cough.
The Radix Astragali, sweet, temperature.Return lung, spleen channel.Invigorating QI to consolidate the body surface resistance, diuresis poison holding, evacuation of pus, expelling pus and promoting granulation.Weak for the deficiency of vital energy, anorexia and loose stool, sinking of QI of middle-JIAO, chronic diarrhea proctoptosis, metrorrhagia of having blood in stool, exterior deficiency spontaneous perspiration, deficiency of vital energy edema, carbuncle difficulty is burst, and burst for a long time and do not hold back, blood deficiency dull yellowish colored skin, interior-heat is quenched one's thirst.
Radix Ophiopogonis, sweet, micro-hardship, is slightly cold.GUIXIN, lung, stomach warp.YIN nourishing and the production of body fluid promoting, lung moistening clears away heart-fire.For dryness of the lung dry cough.Chronic consumptive disease is coughed, and Tianjin wound is thirsty, vexed insomnia, and interior-heat is quenched one's thirst, dryness of the intestine constipation; Pharyngeal diphtheria.
Rhizoma Polygonati Odorati, sweet, be slightly cold.Attach to the lung and stomach meridians.Nourishing YIN to relieve dryness, promoting the production of body fluid to quench thirst.For lung stomach-Yin wound, cough caused by dryness-heat, dry throat and mouth, interior-heat is quenched one's thirst.
Leptoradix Ginseng, returns lung; Stomach warp.QI invigorating; Promote the production of body fluid; Quench the thirst.Main cough is spitted blood; Thirsty; Vomiting.
Bulbus Lilii, sweet, cold.GUIXIN, lung meridian.Nourishing YIN and moistening the lung, clearing away heart-fire for tranquillization.For deficiency of YIN chronic cough, sputum mixed with blood, fidgets due to deficiency is palpitated with fear, insomnia and dreamful sleep, absentminded.
Radix Trichosanthis, sweet, micro-hardship, is slightly cold.Attach to the lung and stomach meridians.Clearing away heat and promoting production of body fluid, detumescence and apocenosis.For calentura excessive thirst, lung-heat type cough, interior-heat is quenched one's thirst, sore swollen toxin.
Herba Dendrobii, sweet, be slightly cold.Return stomach, kidney channel.Reinforcing stomach reg fluid, nourishing YIN and clearing away heat.Lose for cloudy impairment of body fluid, xerostomia excessive thirst, lack of appetite is retched, deficiency-heat after being ill, poor vision.
Herba Hedyotidis Diffusae, sweet, light, cool.Enter stomach, large intestine, small intestine meridian.Heat-clearing and toxic substances removing, inducing diuresis to remove edema, promoting blood circulation and stopping pain.For acute appendicitis (appendicitis), furuncle toxic swelling, jaundice due to damp-heat, the diseases such as dysuria; Furuncle carbuncle is controlled in external, venom.
Radix Glycyrrhizae, sweet, flat.GUIXIN, lung, spleen, stomach warp.Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.For weakness of the spleen and stomach, fatigue and weakness, shortness of breath and palpitation, cough with copious phlegm, the anxious pain of gastral cavity abdomen, extremity contraction, carbuncle sore tumefacting virus, cushion toxicity, strong.
Worn with age according to old people, caused by diseases caused by exogenous pathogenic factor pathogenic wind-warm pyretic toxicity take deficiency of both QI and YIN as this, and phlegm-heat obstructing in the lung is the community acquired pneumonia pathogenic characteristic of mark reality, pharmaceutical composition of the present invention selects Radix Pseudostellariae supplementing QI for promoting the production of body fluid, Radix Astragali tonifying Qi and lifting yang, matches with Radix Pseudostellariae and strengthens QI invigorating effect, the prosperous then hemopoietic of gas; Radix Ophiopogonis nourishing the blood and yin; Above-mentioned three medicines share, and can fill blood, regulate yin-yang.Rhizoma Polygonati Odorati, Leptoradix Ginseng, Bulbus Lilii nourishing YIN to relieve dryness, supplementing QI for promoting the production of body fluid, with aforementioned yin-yang match, clearing away heart-fire for tranquillization.Radix Trichosanthis, Herba Dendrobii, Herba Hedyotidis Diffusae, clearing away heat and promoting production of body fluid, the not stagnant gas of tonify deficiency, is not eliminating evilly just hindering.Radix Glycyrrhizae sour and sweet drugs can transforme into YIN, for making medicine, helps the merit of ginseng stilbene, coordinating the actions of various ingredients in a prescription.Take a broad view of full side, have fill blood, regulate yin-yang, the effect of promoting the production of body fluid, be that medicine card conforms to syndrome of deficiency of both qi and yin community acquired pneumonia, curative effect is obvious.
The technical scheme adopted for solving its technical problem is the pharmaceutical composition of described treatment community acquired pneumonia, be made up of the medicine material of following weight: Radix Pseudostellariae 5-15 part, Radix Astragali 15-25 part, Radix Ophiopogonis 5-10 part, Rhizoma Polygonati Odorati 6-10 part, Leptoradix Ginseng 5-10 part, Bulbus Lilii 10-20 part, Radix Trichosanthis 5-10 part, Herba Hedyotidis Diffusae 1-5 part, Radix Glycyrrhizae 1-5 part.
The preferred technical solution of the present invention is, described pharmaceutical composition of the present invention is obtained by the raw material of following weight portion: Radix Pseudostellariae 10 parts, the Radix Astragali 20 parts, Radix Ophiopogonis 8 parts, Rhizoma Polygonati Odorati 8 parts, Leptoradix Ginseng 8 parts, Radix Trichosanthis 8 parts, Bulbus Lilii 15 parts, Herba Dendrobii 15 parts, Herba Hedyotidis Diffusae 3 parts, 3 parts, Radix Glycyrrhizae.
Present invention also offers the preparation method of described pharmaceutical composition, specifically comprise the steps: after the raw material Radix Pseudostellariae of above-mentioned weight portion, the Radix Astragali, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Leptoradix Ginseng, Bulbus Lilii, Radix Trichosanthis, Herba Dendrobii, Herba Hedyotidis Diffusae, Radix Glycyrrhizae pulverizing, add 70% ethanol (V/V) of medical material gross weight 10 times amount, heating and refluxing extraction 2 times, each 3 hours, merges and filters, decompression recycling ethanol, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the thick paste of 1.20-1.25, to obtain final product.
Those skilled in the art directly can be used as medicine on obtained active constituents of medicine basis of the present invention to take or add on pharmaceutics acceptable adjuvant routinely technique be prepared into required preparation.As the oral drugs of the solid dosage form such as conventional tablet (dispersible tablet, effervescent tablet, oral cavity disintegration tablet, buccal tablet, chewable tablet, effervescent tablet), capsule (hard capsule, soft capsule), granule, pill (drop pill), powder can be made, the oral drugs of the liquid forms such as syrup, oral liquid, water preparation, mixture, decoction also can be made.Therefore, in this pharmaceutical composition except effective ingredient, pharmaceutically acceptable adjuvant can also be contained.Preferably, pharmaceutical composition of the present invention conveniently preparation technology be prepared into oral liquid, syrup, capsule or powder etc.
The present invention also asks to protect aforementioned pharmaceutical compositions in the purposes of preparation treatment community acquired pneumonia particularly in preparation treatment type of deficiency of both QI and YIN community acquired pneumonia medicine.Known by clinical trial, patient treatment is efficacy evaluation result after 2 weeks, and patient treatment is efficacy evaluation result after 2 weeks, and symptom, sign aspect cure rate are 29.7%, improvement rate 70.3%, effective percentage 100%.According to the change of chest imaging (x-ray) result, evaluate the effect for the treatment of.Result shows: clinical recovery 12 example, effective 16 examples, and effective 9 examples, have no improvement 0 example.In safety evaluatio, there is not toxic and side effects and serious adverse reaction in patient.Thus illustrate use medicine composite for curing community acquired pneumonia of the present invention particularly treat belong to type of deficiency of both QI and YIN community acquired pneumonia medicine card conform to, determined curative effect, safe and reliable, serve the remarkable result for the treatment of both the principal and secondary aspects of a disease.Can be used as the effective ways for the treatment of type of deficiency of both QI and YIN community acquired pneumonia, be worth of widely use in clinical.
Detailed description of the invention
Further describe the present invention below by way of specific embodiment, but the present invention is not limited only to following specific embodiment.Within the scope of the invention or not departing from content of the present invention, spirit and scope, the change carried out the present invention, combination or replacement, be apparent for a person skilled in the art, and be included within the scope of the present invention.
embodiment 1
The each raw material of the present invention is taken: Radix Pseudostellariae 5 parts, the Radix Astragali 15 parts, Radix Ophiopogonis 5 parts, Rhizoma Polygonati Odorati 6 parts, Leptoradix Ginseng 5 parts, Bulbus Lilii 10 parts, Radix Trichosanthis 5 parts, Herba Dendrobii 10 parts, Herba Hedyotidis Diffusae 1 part, 1 part, Radix Glycyrrhizae by following weight portion.
embodiment 2
The each raw material of the present invention is taken: Radix Pseudostellariae 15 parts, the Radix Astragali 25 parts, Radix Ophiopogonis 10 parts, Rhizoma Polygonati Odorati 10 parts, Leptoradix Ginseng 10 parts, Bulbus Lilii 20 parts, Radix Trichosanthis 10 parts, Herba Dendrobii 20 parts, Herba Hedyotidis Diffusae 5 parts, 5 parts, Radix Glycyrrhizae by following weight portion.
embodiment 3
The each raw material of the present invention is taken: Radix Pseudostellariae 15 parts, the Radix Astragali 25 parts, Radix Ophiopogonis 10 parts, Rhizoma Polygonati Odorati 10 parts, Leptoradix Ginseng 10 parts, Bulbus Lilii 10 parts, Radix Trichosanthis 5 parts, Herba Dendrobii 10 parts, Herba Hedyotidis Diffusae 1 part, 1 part, Radix Glycyrrhizae by following weight portion.
embodiment 4
The each raw material of the present invention is taken: Radix Pseudostellariae 5 parts, the Radix Astragali 15 parts, Radix Ophiopogonis 5 parts, Rhizoma Polygonati Odorati 6 parts, Leptoradix Ginseng 5 parts, Bulbus Lilii 20 parts, Radix Trichosanthis 10 parts, Herba Dendrobii 20 parts, Herba Hedyotidis Diffusae 5 parts, 5 parts, Radix Glycyrrhizae by following weight portion.
embodiment 5
The each raw material of the present invention is taken: Radix Pseudostellariae 10 parts, the Radix Astragali 20 parts, Radix Ophiopogonis 8 parts, Rhizoma Polygonati Odorati 8 parts, Leptoradix Ginseng 8 parts, Radix Trichosanthis 8 parts, Bulbus Lilii 15 parts, Herba Dendrobii 15 parts, Herba Hedyotidis Diffusae 3 parts, 3 parts, Radix Glycyrrhizae by following weight portion.
The preparation technology of embodiment 1-5 is as follows: after the raw material Radix Pseudostellariae of above-mentioned weight portion, the Radix Astragali, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Leptoradix Ginseng, Bulbus Lilii, Radix Trichosanthis, Herba Dendrobii, Herba Hedyotidis Diffusae, Radix Glycyrrhizae being pulverized, add 70% ethanol (V/V) of medical material gross weight 10 times amount, heating and refluxing extraction 2 times, each 3 hours, merge and filter, decompression recycling ethanol, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the thick paste of 1.20-1.25, to obtain final product.Those skilled in the art directly can be used as medicine on this basis and be taken or add adjuvant conventional formulation technique and obtain the conventional oral formulations such as oral liquid, water preparation, electuary, capsule or powder.
When using medicine composite for curing community acquired pneumonia of the present invention to demonstrate,prove, take prepared oral liquid, every bottle contains crude drug amount 10g, each 1 bottle, 2 times on the one.Take prepared electuary or powder, every bag contains crude drug amount 5g, each 2 bags, 2 times on the one.
the clinical observation of embodiment 6 medicine composite for curing community acquired pneumonia of the present invention
1, case-data: patient 37 example meeting community acquired pneumonia (syndrome of deficiency of both qi and yin) diagnostic criteria selecting hospital ward and outpatient clinic
In select 37 routine clinical cases, man 17 example, female 20 example, age 25-78 year, 63 years old mean age, mild 22 example, middle disease 15 example.
2, diagnosis basis:
1) the tcm diagnosis standard of wind-warm lung-heat disease
(1) with fever of the body, cough, excessive thirst, or out of breath, chest pain is accompanied to be primary symptom.
(2) the visible high fever of sick severe one, Blushing, dysphoria, unconsciousness and delirium, or the disease such as extreme cold of the limbs.
(3) winter and spring is more.Have the advantages that onset is anxious, the change of disease is fast, the course of disease is short.
(4) blood leukocytes sum and neutrophilic granulocyte rising person, belong to bacterial infection; Person normal or on the low side is based on viral infection.
(5) there is consolidation sign in pulmonary, or audible and dry moist rale.
(6) sputum direct smear or cultivation can find pathogen.
(7) fluoroscopy of chest or take the photograph sheet, the visible one or both sides lobe of the lung or lung section inflammatory shade.
2) TCM syndrome diagnostic criteria
Deficiency of both QI and YIN: body febrile lysis, dry cough expectorant is few and sticky, and spontaneous perspiration god is tired, anorexia xerostomia.The few tongue of red tongue, thready pulse or count accurately.
3) Western medicine diagnose standard: Western medicine diagnose standard is formulated with reference to respirology branch 2006 of Chinese Medical Association " Community-Acquired Pneumonia and treatment guidelines ".Clinical diagnosis foundation:
L cough that () occurs recently, expectoration or original symptoms of respiratory disease increase the weight of, and occur purulent sputum, accompany or do not accompany chest pain;
(2) generate heat;
(3) pulmonary consolidation sign and (or) news and moist sound of trembling;
(4) WBC > 10 × 10
9/ L or < 4 × 10
9/ L, companion or not companion cell shift to left;
(5) chest X-ray display lamellar, patch shape wellability shade or chromic fibrous change, accompany or do not accompany hydrothorax;
Above in the item of (l)-(4) any 1 add the 5th, and except pulmonary tuberculosis, lung tumors, non-infectious Interstitial Lung Disease, pulmonary edema, pulmonary atelectasis, pulmonary infarction, after pulmanory eosinophilia and pulmonary vasculitis etc., can clinical diagnosis be set up.
4) severity Scaling standard
(l) mild pneumonia: meet following 4 persons, mild pneumonia can be diagnosed as:
1. body temperature is lower than 38 DEG C;
2. respiratory function or arterial blood gas measure normal or compare with basic value without worsening;
3. leukocyte is lower than 10 × 10
9/ L;
4. without other complication.
(2) severe pneumonia: possessing in following sign 1 or more person diagnosable is severe pneumonia:
1. disturbance of consciousness;
2. respiratory frequency >=30/min;
3. PaO
2< 60mmHg, PaO
2/ FiO
2< 300, needs row Failure Treated with Mechanical Ventilation;
4. systolic arterial pressure < 90mmHg;
5. concurrent septic shock;
6. x-ray chest films showed bilateral or leafyly to get involved, or in the 48h that is admitted to hospital, pathological changes expands >=50%;
7. oliguria: urine volume < 20mL/h, or < 80mL/4h, or Complicated With Acute Renal Failure needs dialysis treatment.
(3) disease pneumonia in: the state of an illness is person between mild pneumonia and severe pneumonia.
3, inclusive criteria:
(1) age is between 20-85 year;
(2) meet the traditional Chinese medical science and disease, Western medicine diagnose standard, and belong to mild pneumonia or middle disease patients with pneumonia;
(3) " Informed Consent Form " person is signed.
4, exclusion standard:
(1) " Informed Consent Form " person is not signed.
(2) merge intentionally, liver, serious disease and the insane such as kidney and coagulation disorders.
(3) diabetic nephropathy patient.
(4) gestation, preparation gestation or women breast-feeding their children, or have drug allergy history person.
(5) pulmonary is because of other diseases, as chronic obstructive pulmonary disease, active tuberculosis, lung tumors, non-infectious Interstitial Lung Disease, pulmonary edema, pulmonary atelectasis, pulmonary infarction, pulmanory eosinophilia and pulmonary vasculitis are admitted to hospital and Complicating Pneumonia In Patients person.
(6) patient of other drug clinical trial is being participated in.
(7) known maybe may to trial drug and component allergy sufferers thereof.
5, to reject and the standard that comes off:
(1), after case is selected in, find not meet inclusive criteria or meet exclusion standard person;
(2) there is serious adverse events, judge to stop this case clinical trial person according to doctor;
(3) case selected after data not entirely or not by specifying medication person;
(4) in process of the test, experimenter's compliance is poor, and affect the treatment estimator.
6, usage and dosage:
Give Drug therapy of the present invention, electuary prepared by Example 5, every bag, containing crude drug amount 5g, each 2 bags, 2 times on the one, is used in conjunction 2 weeks.
7, efficacy evaluation:
(1) cure: symptom and sign disappear, laboratory and x-ray etc. inspections recover normal.
(2) take a turn for the better: symptom and sign, lab testing etc. make moderate progress, x-ray checks that pulmonary lesions absorbs not yet completely.
(3) do not heal: the state of an illness has no improvement.
8, chest imaging (x-ray) is evaluated:
(1) clinical recovery: the whole absorber of chest x-ray inflammation.
(2) effective: the large portion absorber of chest x-ray inflammation.
(3) effective: chest x-ray inflammatory components absorber.
(4) invalid: chest x-ray inflammation is without obviously change or enlarger.
9, therapeutic effect:
Without rejecting and the case that comes off in therapeutic process, all complete clinical observation.
Patient treatment is efficacy evaluation result after 2 weeks, and symptom, sign aspect cure rate are 29.7%, improvement rate 70.3%, effective percentage 100%.
According to the change of chest imaging (x-ray) result, evaluate the effect for the treatment of.Result shows: clinical recovery 12 example, effective 16 examples, and effective 9 examples, have no improvement 0 example.
In safety evaluatio, there is not obvious toxic-side effects and serious adverse reaction in the front and back clinical observation patient that takes medicine (hepatic and renal function, routine urinalysis, electrocardiogram).
Thus illustrate use medicine composite for curing community acquired pneumonia of the present invention particularly treat belong to type of deficiency of both QI and YIN community acquired pneumonia medicine card conform to, curative effect is obvious, safe and reliable, can be used as the effective ways for the treatment of type of deficiency of both QI and YIN community acquired pneumonia, be worth of widely use in clinical.
Claims (8)
1. treat the pharmaceutical composition of community acquired pneumonia for one kind, it is characterized in that, it is obtained by the raw material of following weight portion: Radix Pseudostellariae 5-15 part, Radix Astragali 15-25 part, Radix Ophiopogonis 5-10 part, Rhizoma Polygonati Odorati 6-10 part, Leptoradix Ginseng 5-10 part, Bulbus Lilii 10-20 part, Radix Trichosanthis 5-10 part, Herba Dendrobii 10-20 part, Herba Hedyotidis Diffusae 1-5 part, Radix Glycyrrhizae 1-5 part.
2. pharmaceutical composition as claimed in claim 1, it is characterized in that, it is obtained by the raw material of following weight portion: Radix Pseudostellariae 10 parts, the Radix Astragali 20 parts, Radix Ophiopogonis 8 parts, Rhizoma Polygonati Odorati 8 parts, Leptoradix Ginseng 8 parts, Bulbus Lilii 15 parts, Radix Trichosanthis 8 parts, Herba Dendrobii 15 parts, Herba Hedyotidis Diffusae 3 parts, 3 parts, Radix Glycyrrhizae.
3. pharmaceutical composition as claimed in claim 1 or 2, it is characterized in that, described pharmaceutical composition is oral formulations.
4. pharmaceutical composition as claimed in claim 3, it is characterized in that, described oral formulations is oral liquid, water preparation, electuary, granule, capsule or powder.
5. pharmaceutical composition as claimed in claim 4, it is characterized in that, described oral formulations is electuary.
6. prepare the method for pharmaceutical composition as claimed in claim 1 or 2 for one kind, it is characterized in that comprising the steps: after the raw material Radix Pseudostellariae of above-mentioned weight portion, the Radix Astragali, Radix Ophiopogonis, Rhizoma Polygonati Odorati, Leptoradix Ginseng, Bulbus Lilii, Radix Trichosanthis, Herba Dendrobii, Herba Hedyotidis Diffusae, Radix Glycyrrhizae pulverizing, add 70% ethanol (V/V) of medical material gross weight 10 times amount, heating and refluxing extraction 2 times, each 3 hours, merge and filter, decompression recycling ethanol, and when the filtrate after merging is concentrated into 75 DEG C, its relative density is the thick paste of 1.20-1.25, to obtain final product.
7. the purposes of pharmaceutical composition as claimed in claim 1 or 2 in preparation treatment community acquired pneumonia medicine.
8. the purposes of pharmaceutical composition as claimed in claim 1 or 2 in preparation treatment type of deficiency of both QI and YIN community acquired pneumonia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410821867.3A CN104547610A (en) | 2014-12-26 | 2014-12-26 | Medicine composition for treating community acquired pneumonia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410821867.3A CN104547610A (en) | 2014-12-26 | 2014-12-26 | Medicine composition for treating community acquired pneumonia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104547610A true CN104547610A (en) | 2015-04-29 |
Family
ID=53065381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410821867.3A Pending CN104547610A (en) | 2014-12-26 | 2014-12-26 | Medicine composition for treating community acquired pneumonia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547610A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687864A (en) * | 2016-03-21 | 2016-06-22 | 广州三得医疗科技有限公司 | Artemisia leaf-containing pharmaceutical composition for treating community-acquired pneumonia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020082329A (en) * | 2001-04-20 | 2002-10-31 | 진수인 | A compound for curing and preventing respiratory diseases |
| CN101199745A (en) * | 2006-12-13 | 2008-06-18 | 天津市中宝制药有限公司 | Medicament for treating cough |
-
2014
- 2014-12-26 CN CN201410821867.3A patent/CN104547610A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020082329A (en) * | 2001-04-20 | 2002-10-31 | 진수인 | A compound for curing and preventing respiratory diseases |
| CN101199745A (en) * | 2006-12-13 | 2008-06-18 | 天津市中宝制药有限公司 | Medicament for treating cough |
Non-Patent Citations (2)
| Title |
|---|
| 刘昌燕等: "《刘弼臣中医儿科疑难病辨证论治》", 31 July 2013, 中国医药科技出版社 * |
| 刘秉乾: "中医为主治疗重症咳喘32例临床观察", 《广西中医药》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105687864A (en) * | 2016-03-21 | 2016-06-22 | 广州三得医疗科技有限公司 | Artemisia leaf-containing pharmaceutical composition for treating community-acquired pneumonia |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103845642A (en) | Composition for clearing away heat and toxic materials and cooling blood and beautifying | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN103721197B (en) | A kind of Chinese medicine for the treatment of chronic pharyngitis | |
| CN104352595A (en) | Traditional Chinese medicine for treating allergic rhinitis and preparation method thereof | |
| CN103830636A (en) | Pharmaceutical composition for treating bronchitis and asthma | |
| CN105031454A (en) | Medicine for treating pulmonary tuberculosis | |
| CN103169883B (en) | Traditional Chinese medicine for treating infantile jaundice | |
| CN104435837A (en) | Pharmaceutical composition for treating spontaneous perspiration and night sweat | |
| CN104435614B (en) | A kind of pharmaceutical composition for the treatment of bed-wetting | |
| CN102580030B (en) | External traditional Chinese medicine composition having effect of reducing blood sugar, preparation prepared from the external traditional Chinese medicine composition, and their preparation method | |
| CN104548029A (en) | Pharmaceutical composition for treating epigastric pain | |
| CN104771697A (en) | Pharacetuical composition for treating cholecystitis | |
| CN104623583A (en) | Asthenia cold abdominalgia treating drug and preparation method of asthenia cold abdominalgia treating drug oral liquid | |
| CN104547610A (en) | Medicine composition for treating community acquired pneumonia | |
| CN104524289A (en) | Medicine composition for treating wind-warm lung-heat diseases | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN105267372A (en) | Traditional Chinese medicine granule for treating postoperative gastrointestinal dysfunction and its preparation method | |
| CN104922528A (en) | Medicine composite for treating malignant pleural effusion and preparation method and purpose thereof | |
| CN104096148A (en) | Traditional Chinese medicine for treating infantile pneumonia | |
| CN104491546A (en) | Application of pharmaceutical composition in preparation of medicine for treating wind-warm lung-heat disease | |
| CN102166340B (en) | Chinese medicine composition for treating sthenia heat edema | |
| CN104491440A (en) | Application of pharmaceutical composition in preparing medicine for treating community-acquired pneumonia | |
| CN104887949B (en) | A kind of Chinese medicine preparation for the treatment of DCM (dilated cardiomyopathy) and preparation method thereof | |
| CN106038959A (en) | Traditional Chinese medicine composition for treating pneumonia and preparation method thereof | |
| CN105687684A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150429 |
|
| RJ01 | Rejection of invention patent application after publication |